Transcript of video
Dr. Anton Titov, MD. You have dedicated your life to treating and helping premature babies who would otherwise die if it were not for the medication that you co-developed. But you still are very active in research now and you are developing a synthetic medication. Can you tell us a little bit more about the synthetic medication that you are developing that supposedly will be much easier to scale up? Dr. Anton Titov, MD. Because you don’t have to take in animal material anymore. Because, of course, if we have one pig, they were not big. It can produce two or three vials of surfactant. At least you can treat 2 3 babies, not more than that. You need huge amount of pigs. Dr. Anton Titov, MD. You can’t scale up too much. Dr. Anton Titov, MD. You can’t treat grown ups with lung diseases. Already in the late 90s, we knew the exact composition of surfactant. Phospholipid composition. The sequence of the peptides. Dr. Tore Curstedt. We thought that in the end of the 90s, beginning 2000, we will have a synthetic surfactant. But we had problem because we tried to make recombinant peptides. The proteins, SPB and SPC, it was no problem to get the right sequence. But SPC, for example, is an alpha helix. But it was not an alpha helix, when we made a recombinant SPC. Medical second opinion is important. Dr. Anton Titov, MD. Dr. Tore Curstedt. That was the problem. The structure, three-dimensional structure. Then we had to start making analogs. Have made many different analogs during the last 20 years. Now, we have two very good analogs. Dr. Tore Curstedt. We have combined these analogs with phospholipids and we have tested it in our rabbit models. Also safely studied in three countries, in Czech Republic. In Germany and England. It functions very well. Clinical trial has started a couple of months ago, an it will start in Europe.